

**IN THE CLAIMS:**

Please cancel claims 2 and 11 without prejudice to prosecute them in a subsequent application.

Please amend claims 1, 3, 4, 5, 7, 10, 12, 15, 16, 17 and 80 (renumbered as 68) as shown on the attached "Claim Sheets marked-up to show changes."

A clean copy of all pending claims is attached as "Clean Set of Claims."

**REMARKS**

The above amendments to the claims find support throughout the specification including at page 13, lines 11-19, page 16, lines 16-27, and page 17 line 5 to page 19, line 7. In view of these amendments and the following remarks supported by the appended Declaration of Neil H. Bander (**Exhibit 1; "Bander Declaration #1"**), submitted during prosecution of the related case serial number 08/838,682, issued as U.S. Patent 6,107,090 on August 22, 2000, and the Declaration of Neil H. Bander (**Exhibit 2; "Bander Declaration #2"**) submitted during prosecution of the related case serial number 08/895,914, issued as U.S. Patent No. 6,136,311 on October 24, 2000, the pending claims of the present application are in condition for allowance and reconsideration of the rejections in the outstanding office action is respectfully requested.

The claims pending in this application are 1, 3-10, 12-19 and 68 directed to methods of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells using antibodies or antigen binding portions thereof which bind to the extracellular domain of prostate specific membrane antigen present as an integral membrane protein in a living cell.